TMS Co Ltd
TMS Co Ltd provides healthcare diagnostic services and related research, primarily generating revenue through diagnostic testing and medical research activities.
Business. TMS Co Ltd (4891.T) is a Japanese biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. Headquartered in Japan, the company is listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TMS Co Ltd (4891.T) is a Japanese biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. Headquartered in Japan, the company is listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
TMS Co Ltd exhibits a highly liquid capital structure, with cash and equivalents amounting to ¥34.18 billion, representing 93.2% of total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative leverage profile. The current ratio of 51.12 suggests strong short-term liquidity, well above the typical thresholds for financial stability.
Profitability metrics are negative, with a return on equity of -4.18% and a return on assets of -4.09%. These figures indicate that the company is currently generating losses relative to its equity and asset base. The operating and net income are both negative, at ¥-1.52 billion and ¥-1.49 billion, respectively, signaling a need for operational improvements or cost reductions to achieve profitability.
The company's revenue is concentrated in its healthcare diagnostics segment, with no disclosed geographic diversification in the provided data. This lack of geographic segmentation suggests potential exposure to regional market risks, particularly in Japan, where the company is headquartered. The absence of detailed segment reporting limits the ability to assess the performance of individual business lines.
Looking ahead, the company's growth trajectory is uncertain. No specific revenue growth rates or outlooks are provided in the input data, and the current FY outlook does not include numeric deltas. Analysts have assigned a mean price target of ¥620.00, with a strong buy recommendation, but this does not necessarily reflect near-term operational performance.
Risk factors for TMS Co Ltd include the current unprofitable operations and the potential for future dilution, although the risk assessment indicates that dilution is currently low. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is assessed as low. However, the negative returns on equity and assets suggest that the company may need to raise additional capital in the future, which could lead to share dilution.
Recent events and filings do not indicate any major corporate actions or strategic shifts. The company's financial snapshot does not include recent earnings call transcripts or 10-K filings, so the narrative is based on the latest available financial data. The lack of recent events or strategic announcements suggests a stable but unremarkable operational environment.
- TMS Co Ltd has a highly liquid balance sheet with no long-term debt and a current ratio of 51.12.
- The company is currently unprofitable, with negative returns on equity and assets.
- Revenue is concentrated in the healthcare diagnostics segment, with no geographic diversification disclosed.
- Analysts have assigned a strong buy rating, but the company's operational performance remains a concern.
- The risk of dilution is currently low, but the company may need to raise capital in the future to address its losses.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income +42,3% YoY; Net income +42,2% YoY.
- ▍Operating income +42,3% YoY
- ▍Net income +42,2% YoY
Operating income +9,9% YoY; Net income +9,3% YoY.
- ▍Operating income +9,9% YoY
- ▍Net income +9,3% YoY
Operating income −84,4% YoY; Net income −11,5% YoY.
- ▍Operating income −84,4% YoY
- ▍Net income −11,5% YoY
- ▍Free cash flow −10,2% YoY
Operating income −145,8% YoY; Net income −179,9% YoY.
- ▍Operating income −145,8% YoY
- ▍Net income −179,9% YoY
- ▍Free cash flow −181,2% YoY
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -25,00 |
| Revenue | —no estimate | —no estimate | 0 JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- TMS Co Ltd Market data — financials · 2026-05-26
- TMS Co Ltd Market data — analyst estimates · 2026-05-26